Boris Peaker
Stock Analyst at TD Cowen
(2.06)
# 2,884
Out of 4,876 analysts
19
Total ratings
36.36%
Success rate
9.73%
Average return
Main Sectors:
Stocks Rated by Boris Peaker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Downgrades: Hold | n/a | $1.19 | - | 3 | May 10, 2024 | |
| LNTH Lantheus Holdings | Initiates: Outperform | $100 | $81.49 | +22.71% | 1 | Dec 4, 2023 | |
| ADCT ADC Therapeutics | Downgrades: Market Perform | n/a | $2.71 | - | 1 | Nov 9, 2023 | |
| PCRX Pacira BioSciences | Upgrades: Outperform | $50 | $23.48 | +112.95% | 1 | Aug 3, 2023 | |
| PCVX Vaxcyte | Initiates: Outperform | n/a | $32.58 | - | 1 | Apr 18, 2023 | |
| XNCR Xencor | Initiates: Outperform | n/a | $8.14 | - | 1 | Dec 6, 2022 | |
| EBS Emergent BioSolutions | Maintains: Market Perform | $30 → $29 | $6.35 | +356.69% | 1 | Sep 12, 2022 | |
| CTMX CytomX Therapeutics | Downgrades: Market Perform | n/a | $2.25 | - | 2 | Jul 11, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Market Perform | n/a | $25.76 | - | 1 | Mar 15, 2022 | |
| NCNA NuCana | Downgrades: Market Perform | n/a | $0.09 | - | 1 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.54 | - | 1 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $560.14 | - | 1 | Jun 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $95 → $102 | $79.10 | +28.95% | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.40 | - | 1 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.73 | - | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.29 | - | 1 | Jul 24, 2017 |
MacroGenics
May 10, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.19
Upside: -
Lantheus Holdings
Dec 4, 2023
Initiates: Outperform
Price Target: $100
Current: $81.49
Upside: +22.71%
ADC Therapeutics
Nov 9, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.71
Upside: -
Pacira BioSciences
Aug 3, 2023
Upgrades: Outperform
Price Target: $50
Current: $23.48
Upside: +112.95%
Vaxcyte
Apr 18, 2023
Initiates: Outperform
Price Target: n/a
Current: $32.58
Upside: -
Xencor
Dec 6, 2022
Initiates: Outperform
Price Target: n/a
Current: $8.14
Upside: -
Emergent BioSolutions
Sep 12, 2022
Maintains: Market Perform
Price Target: $30 → $29
Current: $6.35
Upside: +356.69%
CytomX Therapeutics
Jul 11, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.25
Upside: -
Nektar Therapeutics
Mar 15, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $25.76
Upside: -
NuCana
Mar 3, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.09
Upside: -
Jul 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.54
Upside: -
Jun 12, 2017
Initiates: Outperform
Price Target: n/a
Current: $560.14
Upside: -
Jun 27, 2022
Maintains: Market Perform
Price Target: $95 → $102
Current: $79.10
Upside: +28.95%
Aug 13, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.40
Upside: -
Oct 22, 2018
Initiates: Outperform
Price Target: n/a
Current: $0.73
Upside: -
Jul 24, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.29
Upside: -